Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotech firm Callisto Pharmaceuticals has received positive preliminary results from the company's drug, SP304, which is currently being evaluated pre-clinically for the treatment of inflammatory bowel diseases. Data showed a pronounced reduction of inflammation following treatment with SP304.
Subscribe to our email newsletter
The drug was evaluated in a TNBS-induced ulcerative colitis mouse model, which is an animal model widely used to evaluate drug candidates for treatment of human inflammatory bowel diseases (IBD). SP304 demonstrated a significant reduction in histopathological indicators of inflammation.
SP304, an orally deliverable and highly stable peptide, is an analog of the native human peptide uroguanylin, a guanylate cyclase receptor agonist (GCRA) normally produced in the intestinal tract. SP304, unlike the parent peptide uroguanylin, exists in a single active conformer, and is an excellent candidate for drug development.
“The histopathology data demonstrating the anti-inflammatory properties of SP304 are particularly impressive because the peptide was administered once a day at very small doses of 0.01-0.02 mg,” remarked Dr Kunwar Shailubhai, senior vice president of discovery research at Synergy Pharmaceuticals, a wholly owned subsidiary of Callisto Pharmaceuticals.